A delivery form, not a distinct active ingredient: under a tenth of the capsule weight is magnesium, the rest taurine. Lower blood pressure, better blood sugar handling and fewer migraine attacks follow from the magnesium, mostly tested as other magnesium salts. Nothing yet shows the pairing outperforms cheaper forms. Diarrhea dominates safety, with magnesium build-up where kidney filtering is reduced. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Serum magnesium | 0.85–0.95 mmol/L (2.07–2.31 mg/dL) | Confirms repletion; the only magnesium measure with outcome data |
| Red-blood-cell magnesium | 5.5–6.5 mg/dL | Reflects intracellular stores, which serum does not |
| Creatinine with eGFR | Above 60 mL/min/1.73 m² | The safety gate: determines whether magnesium can be cleared |
| Home systolic and diastolic blood pressure | Below 120/80 mmHg | The endpoint with the strongest supporting evidence |
| Serum potassium | 4.0–4.5 mmol/L | Magnesium repletion is required for potassium correction; the two move together |
| Serum calcium with albumin | 9.0–10.0 mg/dL | Detects the calcium-magnesium imbalance that mimics magnesium deficiency symptoms |
| HbA1c | 5.0–5.4% | Tracks the glycemic benefit where one exists |
| High-sensitivity C-reactive protein | Below 1.0 mg/L | Tracks the contested anti-inflammatory claim |
| Plasma taurine | No established optimal target; change from the individual's own baseline is what to track | Documents whether the taurine load is actually raising exposure |
Cadence: Serum magnesium and kidney function at 8–12 weeks, then every 6–12 months while dosing continues; home blood pressure weekly for the first month, then monthly; glucose markers annually. An earlier recheck follows filtration falling below 60 mL/min/1.73 m² or starting a diuretic or acid-suppressing drug.